Drug · DIN 02486032
VIZIMPRO
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since November 24, 2021; first marketed April 22, 2019.
- Drug Identification Number (DIN)
- 02486032
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Dacomitinib L01EB07
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DACOMITINIB (DACOMITINIB MONOHYDRATE) | 30 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 26, 2019: NOC 21898New Drug Submission (NDS)
Other DINs named VIZIMPRO
- DIN 02486024 · Cancelled Post Market
- DIN 02486040 · Cancelled Post Market